Neoadjuvant Nivolumab Plus Chemotherapy Improves OS Among Patients with Resectable NSCLC as Compared with Chemotherapy Alone By Ogkologos - June 24, 2025 890 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 816 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes European Parliament (EP) report on Psychosocial Risks (PSR) at Work as a Key Step towards Protecting the Cancer Workforce and Ensuring High-Quality... FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumours ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership MOST POPULAR What Survivors Should Know When Transitioning From Cancer Care to Primary... April 4, 2023 On Giving Tuesday, You Helped Us Raise $334,449 For People, Pets,... December 13, 2019 What Are Clinical Practice Guidelines and How Do They Impact Care... May 27, 2022 Clinics Offering “Mammoglam” Services to Encourage More Women to Get Mammograms June 12, 2019 Load more HOT NEWS FDA Approves Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate... EMA Reminds Physicians to Use Atezolizumab with Nab-paclitaxel for Treating TNBC Her Wedding Ceremony Was Interrupted By A Voice In The Back,... Potential for Larger Gene Panels to Increase the Number of Molecularly...
